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Abstract
Background: Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD). For current
smokers who are diagnosed with COPD, their first treatment option is to stop smoking. Motivation is necessary
for long-term smoking cessation; therefore, when designing smoking cessation programs, the patients’ needs
and preferences should be considered. We focused on COPD patients’ experiences with existing smoking
cessation programs and evaluated their preferences for the improvement of these programs.
Methods: We conducted 18 guideline-based interviews with COPD patients between April and June 2014 in
Germany. Each patient with COPD, who was a current or past smoker and had made at least one attempt to
quit smoking in the past 5 years, was included in the study. We audiotaped, verbatim transcribed, and evaluated
the interviews, using content analysis.
Results: The patients had broad and different experiences with pharmaceutical, behavioral, and alternative
approaches that supported or negatively influenced the smoking cessation process. Pharmaceuticals were viewed
as an expensive alternative with many side effects although they helped to stop cravings for a few moments.
Furthermore, the bad structure and impersonal content of the seminars for smoking cessation negatively
influenced group cohesion, and therefore degrading the patients’ motivation to stop smoking. Alternative
methods, such as acupuncture and hypnosis were mostly ineffective in smoking cessation, but in some cases,
served as motivational strategies.
Conclusion: Negative experiences with smoking cessation were explained by the patients’ lack of motivation
or resolution. Other negative experiences, such as the structure of seminars for smoking cessation and the high
price of pharmaceuticals should be addressed through policy changes to increase the patients’ motivation to quit
smoking.
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Background
The Global Burden of Disease Study estimates that
chronic obstructive pulmonary disease (COPD) will be-
come the third leading cause of death worldwide by
2020 [1]. The Global Initiative for Chronic Obstructive
Lung Disease defines COPD as ‘a common preventable
and treatable disease which is characterized by persistent
airflow limitation that is usually progressive and associ-
ated with an enhanced chronic inflammatory response
in the airways and the lung to noxious particles or gases’
[2]. An important risk factor, although not the only one,
for the high prevalence of COPD in Germany and other
industrial nations is smoking. According to the estimates
by the World Health Organization, 73 % of COPD-
related cases of death are caused by smoking [3]. The
percentage of lifelong smokers who develop COPD is
40–50 % [4].
Another important consequence of COPD is the eco-
nomic burden. According to estimations in the European
White Book, the amount spent on COPD is approximately
38.6 billion Euros, which represents 56 % of the total dir-
ect costs of respiratory diseases [4]. COPD is not curable;
however, stopping smoking is the most effective way to
prevent the exacerbation of the disease and to maintain
a state of health. Hence, after a COPD diagnosis, smok-
ing cessation is the first and most important treatment
option [2].
Nevertheless, smoking cessation can be very difficult
for patients with COPD, and there are no single factors
that predict long-term success. Different behavioural and
pharmaceutical interventions support smoking cessation
[5]. Behavioural interventions encompass psychological
counselling (face-to-face or telephone), self-help mea-
sures (books, apps, and the Internet), individual or group
therapy, and alternative remedies, such as acupuncture.
Nicotine replacement therapy (NRT), bupropion, and
varenicline are examples of pharmaceutical interven-
tions. Many support programs may increase COPD
patients’ motivation to stop smoking and their chances
for success. However, it is unclear if these programs cor-
respond to the preferences of COPD patients who wish
to stop smoking and if these interventions changed the
patients behavior. Michi et al. identified different sources
of behaviour that could prove fruitful targets for inter-
vention [6]. According to this information Michi et al.
developed the COM-B framework which is based on an
interacting system involving the components of capabil-
ity (C), opportunity (O), motivation (M) and behavior (B).
Therefore this framework shows that the success of in-
terventions for smoking cessation is based on different
perspectives. In the literature different qualitative studies
have evaluated the factors that do and do not motivate
smokers with COPD to stop smoking [7–10]. Wilson [7]
and van Eklund [9] et al. reported reasons why patients
with COPD did not quit smoking, which included diffi-
culty breaking lifelong habits and feeling that it was too
late for them to stop smoking. The patients also re-
ported that the demands of other people could lead to
the continuation of smoking. Support from relatives and
care providers during smoking cessation were welcomed
by these patients but they wanted to make the decision
to quit on their own. Two studies conducted by van
Eerd et al. analysed the differences in smoking and quit-
ting behaviours between patients with and those without
COPD [8, 10]. One of these studies concluded that the
smokers with COPD did not believe in the efficacy of
smoking cessation aids, although these smokers used the
different aids more often than the smokers without
COPD did [8, 10]. Nevertheless no study compared pa-
tients with COPD who had successfully stop smoking
with patients who are unable to quit smoking. Therefore
it is important to compare the preferences and motivat-
ing aspects for different smoking cessation intervention
in both groups to identify factors that explain success
and failure of interventions. Smoking cessation interven-
tions also differ in structure and reimbursement systems
between industrial nations. For Germany there is lack of
studies that give a broad overview about the experiences
and preferences of patients with COPD for different
forms of smoking cessation interventions.
The aim of the present study was to analyse the expe-
riences of smokers and former smokers with COPD
with existing smoking cessation programs and to evalu-
ate the smokers’ preferences for the improvement of
the programs. These preferences will be classified into
the three components of the COM-B Model to analyse
the different factors that could influence the behaviour
of patients with COPD. Therefore, we chose to inter-
view patients with COPD who were current or former
smokers and who had tried to quit smoking in the past
5 years.
Methods
Study design and population
To elicit patients’ personal experiences and their views
on the smoking cessation process, we used a qualitative
research design, as it focuses on the subjective perspec-
tive of the observed.
This study was approved by the Committee for
Clinical Ethics of the Hannover Medical School (MHH),
Germany (2214-2014). We conducted semi-structured,
guideline-based interviews with COPD patients, and we
recruited the study’s sample by asking primary care physi-
cians, pulmonologists, and university clinics to distribute
information flyers and post requests for participation on
COPD social-networking sites. Patients who were current
smokers or had smoked previously and who had made at
least one attempt to stop smoking in the past 5 years were
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recruited. We decided to use the time frame of the past
5 years because a longer time frame would have made it
difficult for the patients to recall their experiences in suffi-
cient detail. To capture different experiences from all the
patients in this study, we maximized the variation in our
sample by including men and women from different social
backgrounds and ages, who had used different smoking
cessation methods (e.g. medication, group counselling,
hypnosis). Because of the time frame of the project and
the patients’ wishes, a research assistant from the institute
(Tedja) conducted four interviews in the patients’ homes
and 14 interviews via telephone. The number of inter-
views was not predefined. We always conducted three to
four interviews and coded them first before we inter-
viewed the next four patients. Therefore, we stopped con-
ducting interviews after no new information emerged.
Prior to conducting the interviews, we obtained written
consent from the patients and gave them additional infor-
mation about the project, via mail. The confidential and
anonymous handling of all personal data was assured. We
provided information to the participants about the study’s
aim, the voluntary nature of their consent, and the proce-
dures for data collection and processing. The research as-
sistant conducted all the interviews between April and
June 2014.
Guidelines
Based on information from the literature and input from
an interdisciplinary group of researchers, we structured
the interviews with the use of two guidelines. These
guidelines were slightly different for smokers and ex-
smokers and were developed according to the COM-B
framework for understanding behavior [6]. The inter-
views consisted of open-ended questions that encour-
aged the COPD patients to talk about their experiences
and preferences regarding the different smoking cessa-
tion processes in their own words. The guideline-based
questions focused on the patients’ experiences with
smoking cessation therapies that they had undergone.
The interview started with questions regarding their mo-
tivation to stop smoking. Therefore, the patients were
asked to describe a situation in which they wanted to
quit smoking. Further questions pertained to their
chosen smoking cessation method, and the reasons for
their selection were scrutinized. During this phase, pos-
sible reasons for choosing different forms of smoking
cessation, such as the effect of other people, the costs,
and time-related reasons were explored. We also asked
the patients about specific aspects of the smoking cessa-
tion methods that helped them make the decision to
quit, what was comfortable, and what kind of support
they needed in order to deal better with the smoking ces-
sation situation. In the last session of the interview,
smokers described the characteristics that a smoking ces-
sation program should not have.
Each question in the guidelines provides information
about the factors (Capability, Opportunity, and Motivation)
that influence and describe the respondents’ behavior [6].
These factors are part of the COM-B framework for under-
standing behavior, which was developed by Michie et al.
The framework hypothesizes that the interaction among
the three components influences the performance of a
behavior. Each component may influence behavior
directly. Thus, Opportunity and Capability might influ-
ence Motivation, which also affects behavior.
Each factor influences one another in a different
manner. Information about capability (psychological
and physical capacity) becomes apparent during the de-
scriptions of a typical situation related to smoking ces-
sation. The necessary knowledge and skills of the
patients about the different ways to stop smoking also
may be identified during the interviews. Therefore, we
first asked the patients to talk about a situation related
to their last attempt to quit smoking. Only towards the
end of describing the situation did we ask the patients
about possible experiences with different methods that
were not mentioned before. The questions also focused
on the patients’ motivation or the brain processes that
energized a direct behavior. This information was ob-
tained by asking questions about the reasons for choos-
ing certain smoking cessation therapies and from the
patients’ descriptions of their experiences with these
methods. The last factor, Opportunity, describes all ex-
ternal factors that make the behavior possible for the
patients [6]. During the interviews, we asked the pa-
tients, if they had support during the smoking cessation
process. We used the COM-B framework to understand
why some patients with COPD used special smoking
cessation aids and others did not. We also wanted to
analyze the influence of the experiences on each of the
three factors.
Methods of qualitative analysis
The interviews lasted approximately 1 h, and we audio-
taped and verbally transcribed them. One research assist-
ant who was not involved in the interviews, transcribed
them, and another assistant reviewed the audio recordings
and transcripts to verify the accuracy of the first transcrip-
tion. As the interviews were conducted in German, the
citations were translated by two professional translators
who are native speakers. Disparities were clarified bi-
laterally. Furthermore, each interview was completely
anonymous.
We analysed the data using content analysis methods.
The analysis involved interpreting and paraphrasing rele-
vant text independently through content analysis with
the inclusion of inductive categories [11, 12]. To ensure
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accuracy of the analysis, two researchers (Tedja and
Aumann) independently read the interviews, paraphrased
the relevant text using the MAXQDA program, and
generated a preliminary codebook. First, the researchers
analysed the text based on deductive categories, which we
derived from the questions in the guideline. The inductive
categories were developed independently by each inter-
viewer from the content of the interview. Disagreements
were discussed between the two researchers and resolved
by consensus. In order to obtain an overall impression of
the content of the interviews, the researchers read and re-
read the transcripts and revised the coding system accord-
ingly. In subsequent discussions, the researcher checked
the codes for consistency and agreement, and resolved
any differences by an iterative process. The aim of a con-
tent analysis is to identify cross-relationships, repetitions,
commonalities, and differences in the statements to detect
any trends regarding the results. To achieve this, all inter-
pretations and arguments were documented and sup-
ported by citations.
Results
Eighteen COPD patients (seven men; 11 women) partici-
pated in the interviews. We stopped the interviews when
the main elements were repeated in the last three inter-
views. The average age of the patients at the time of the
interviews was 57 years. Five of the 18 patients still
smoked and the average age at which the patients began
smoking was 17 years. Table 1 presents the patients’
characteristics in detail.
With regards to the research questions, we obtained
information about the patients’ experiences with
pharmaceutical, behavioral, and alternative smoking
cessation therapies, and their preferences for improv-
ing the smoking cessation process.
Experiences with pharmaceutical support
Three different pharmaceutical therapies for smoking ces-
sation - varenicline, NRT, and bupropion - are available
for patients in Germany. Most of the interviewed patients
had heard about the different forms of NRT, especially the
gum and patch (see Table 2). The medication bupropion
was less familiar than varenicline. Some patients had tried
varenicline therapy and nearly all had used some form of
NRT; however, none of them had tried bupropion. All the
patients who had tried varenicline agreed that its high cost
and powerful side effects, such as nausea and the more
rarely reported side effects of deafness and loss of body
control, were significant disadvantages.
“I found it [Vareniclin] absolutely terrible. I had the
feeling that I was under the influence of drugs, you
know?” (No. 8, f, 56 years)
“There was just the disadvantage that I was spending
money on something that didn’t help me.” (No. 4, m,
50 years)
Table 1 Evaluation of the socioeconomic questionnaire
No. Sex Age Marital status Age of starting smoking Years since quit Number of years smoked Profession
1 Female 53 Married 35 3 15 Office clerk
2 Male 62 Married 21 2 39 Banker with management position
3 Female 54 Widowed 14 Current smoker 14 Bookseller
4 Male 50 Married 15 4 31 Branch manager
5 Female 59 Single 17 3 39 Nurse
6 Female 65 Widowed 20 Current smoker 45 Insurance clerk
7 Male 58 Married 13 2 43 Surveying technicians
8 Female 56 Married 15 1 40 Geriatric nurse
9 Female 53 Married 16 1 36 Notary clerk
10 male 54 Married 19 1 34 Professional soldier
11 Female 49 Married 14 1 34 Tax officer
12 Female 59 Married 14 4 41 Nurse
13 male 59 Relationship 15 Current smoker 44 Office machine repairer
14 Female 56 Divorced 17 5 34 Office clerk
15 male 59 Married 14 2 43 Seller
16 female 59 Widowed 15 Current smoker 44 Tax officer
17 male 59 Single 14 1 44 Project leader
18 female 64 Relationship 17 Current smoker 47 Postal clerk
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Patients provided varied feedback regarding the effi-
cacy of treatment with varenicline. Some patients had
successfully stopped smoking, and one patient reported
a reduction in smoking cravings.
“And then I noticed: It works! I don’t smoke anymore.
And then, from one moment to the next … I stopped
smoking.” (No. 12, f, 59">years)
Apart from therapy with varenicline, patients also had
various experiences with NRT in the form of nicotine
patches and nicotine chewing gum. None of the patients
had tried other forms of NRT, such as lozenges, inhalers,
or nasal sprays. For one patient, who used the nicotine
patch, the dosage was so low that the person unintention-
ally continued smoking while they were wearing the patch.
Another patient who had tried the nicotine patch was
smoke free for 30 months. The main limitations of the
nicotine patch that was cited by the patients were their
high cost, the side effect of a tingling sensation in the
hands, and the daily changes in the skin that came into
contact with the patch. According to the patients, al-
though the nicotine chewing gum was ineffective in help-
ing them stop smoking completely, it did help them take a
deep breath, and thereby attenuate smoking cravings.
“These (nicotine) chewing gums … and at that
moment, you get about half an hour’s breathing room:
three quarters of an hour in which you really don’t
gasp for a cigarette, but rather can really let out a
deep breath and say, “Oh thank God, peace at last.”
(No. 7, m, 58 years)
In particular, the users of nicotine chewing gum fre-
quently cited a bad taste and stronger cigarette cravings
as limitations of this form of NRT. In addition, some
patients mentioned experiencing an accelerated pulse
and tingling sensation in the hands. However, they stated
that the therapy was easy to use.
“Yes, but the disadvantages are that they taste so
disgusting hey? That one has to chew them for about
five minutes and can then throw them away – they
have such an awful aftertaste.” (No. 14, f, 56 years)
The interviews revealed differences between the current
smokers and ex-smokers. Both groups often used nicotine
substitutes during the smoking cessation process. It was
found that the ex-smokers often combined the use of
nicotine substitutes with a strong resolve to stop smoking,
and viewed this as further motivation to stop smoking.
Table 2 Information about medications
No. Have heard about … Have used …




1 ✓ X ✓ X ✓ ✓ (patches, gums) X X
2 ✓ ✓ ✓ X X ✓ (patches, gums) X X
3 ✓ X ✓ ✓ ✓ ✓ (patches, gums) X X
4 ✓ ✓ ✓ X X ✓ (patches, gums) X ✓
5 X X ✓ X X ✓ (gums) X X
6 ✓ ✓ ✓ X X ✓ (patches) X X
7 ✓ X ✓ X X ✓ (patches) X X
8 ✓ X ✓ X ✓ ✓ (patches, spray) X ✓
9 ✓ ✓ X X X X X X
10 ✓ X ✓ ✓ ✓ X X X
11 ✓ X X X X X X X
12 X X X ✓ ✓ X X ✓
13 X X X X X X X X
14 ✓ n.a. ✓ X X ✓ (gums) X X
15 ✓ ✓ ✓ X X ✓ (gums) X X
16 ✓ n.a. ✓ X n.a. X X X
17 ✓ ✓ ✓ X ✓ ✓ (gums) X X
18 ✓ ✓ X X ✓ ✓ (patches) X ✓
✓ have heard about the medication or have used it
X not known before or not used before
n.a. not available
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They did not think that it was possible to stop smoking
only with the use of medications. This group also reported
the side effects and negative experiences in detail
Of the few current smokers who were interviewed, all
reported unintentionally taking nicotine substances.
They had forgotten that they had applied their nicotine
patch, so that the patch’s effect was not felt or was not
detected by the patients.
In summary, we can ascertain that the success achieved
through pharmaceutical support varied widely among the
patients, and they often complained about the side effects
and the high cost of this form of treatment. Nevertheless,
pharmaceutical support was considered helpful in redu-
cing smoking cravings.
Experiences with behavioural support
Some patients had also tried reading self-help books,
attending smoking cessation seminars, and participating
in self-help groups. Patients did not find self-help books
helpful; because of their lack of appeal, the patients con-
sidered them unsuitable.
“I understood what was written there, but I didn’t
have the feeling that it also applied to me. So now, to
me, yes? Well, everybody else can do that, but for me,
it won’t work anyway.” (No. 2, m, 62 years)
Compared to the number of patients who had tried
self-help books, more patients had attended smoking
cessation seminars, especially during rehabilitation (see
Table 3). The smoking cessation seminars during re-
habilitation provided practical advice for daily life and
information on the smoking cessation process, and
they involved the use of visual presentation. The group
cohesion that developed among the participants of
these seminars was considered helpful. Moreover, this
finding indicated that the smokers wished support
from other smokers who were in the same situation,
and that strong group cohesion was motivational for
the smokers.
“Yeah … I enjoyed the group and that the group stuck
together – the whole group really stuck together – we
also stuck to doing what the therapist said.” (No. 14, f,
56 years)
Nevertheless, some patients felt fearful and ashamed
when they reported that their attempted smoking cessa-
tion was unsuccessful. These patients also mentioned
this when discussing their experiences with self-help
groups (only some patients had participated in self-help
groups). This topic was not mentioned by the smokers
who reported to be part of a strong group cohesion. One
assumption is that the strong group cohesion reduced fear
and/or shame, and therefore, increased the effectiveness
of the program.
“Besides being terribly ashamed of yourself in front of
the others for having smoked again, it brought
nothing.” (No. 4, m, 50 years)
In this context, the patients felt that a mutual exchange
of experiences was extremely important in motivating a
person to stop smoking, and that peer pressure increased
this motivation. Therefore, they preferred that the atmos-
phere during self-help groups and smoking cessation sem-
inars be very friendly and one that equips the participants
with a sense of confidence.
Patients also mentioned that the other limitations of
smoking cessation seminars and self-help groups were the
lack of flexibility in the organisational structure, and that
their content was often illogical. In particular, patients felt
that the moderators were not well qualified. Therefore,
they did not consider these meetings effective, as they
failed to help them to achieve tobacco abstinence.
“… Are you going to do the ‘non-smoker’ course? Oh
no, not again.” No concept. One simply has to tick off.
You hear the same thing three times. The way they do
Table 3 Information about behavioural therapies









1 ✓ ✓ X ✓
2 ✓ ✓ X ✓
3 ✓ ✓ X X
4 ✓ ✓ ✓ ✓
5 ✓ ✓ X X
6 ✓ ✓ X X
7 ✓ ✓ ✓ X
8 X ✓ X ✓
9 X ✓ X ✓
10 ✓ ✓ X X
11 X X X X
12 X X X X
13 X X X n.a.
14 X ✓ X ✓
15 X X X X
16 X ✓ X X
17 ✓ ✓ ✓ X
18 X ✓ n.a. X
✓ have heard about the therapies or have used it
X not known before or not used before
n.a. not available
Aumann et al. Tobacco Induced Diseases  (2016) 14:31 Page 6 of 12
it in the rehabilitation clinics is senseless and
brainless.” (No. 4, m, 50 years)
The comparison between the patients who were current
smokers and those who had stopped smoking showed that
the ex-smokers were better informed about the provision
of smoking cessation seminars and knew about possible
subsidies by health insurance. The current smokers did
not seem to be self-motivated to become informed about
smoking cessation seminars.
“The reporting requirement is missing. As the affected
party, one does not get any information on the options
one has. This is serious, which is what always makes
me a little nervous. Which makes you have a bad
attitude and then you resign and at some point you
say: ‘Then I will not do it anymore!’ That is eventually
the result, which sounds sad. But that’s how it is.”
(No.3, m, 59 years)
“Um i am, I researched on the internet. I have spent
enough time in the rehabilitation centres and then I
met the ‘Happy non-smokers’.” (No. 8, f, 56 years)
Based on the experiences that patients had with
smoking cessation seminars during rehabilitation or
self-help groups, most of them wished to participate
in an entire rehabilitation program only for smoking
cessation. They preferred a program based on the
existing treatment modalities for alcoholics and drug
addicts located in therapy centres, rather than in
homes, for a minimum of 1 week and a maximum of
3 months.
“I found it really terrible that for alcoholics but also
for, what do I know – drug addicts etc. There is only
one detox method – one option for detox – where they
can say ‘I’m going to some clinic and I’m going to stay
there for 6 weeks or 3 months, or what do I know?”
(No. 1, f, 53 years)
A rehabilitation program must have certain charac-
teristics that are important, so that patients will par-
ticipate in it. These characteristics may be derived
from patients’ negative experiences with smoking ces-
sation seminars and their preferences for an ideal
smoking cessation program. Therefore, rehabilitation
should include comprehensive support, a pleasant at-
mosphere, a combination of medication support, a
comprehensive sport and nutrition program, and a
wellness area. The patients in the study considered
these activities important as they allowed them to take
a break from their daily routine and decreased side effects,
such as weight gain. The patients’ main expectation for
this treatment was that the smoker would learn strategies
to stop smoking and manage the withdrawal symptoms in
their daily lives.
“Sport, leisure-time activities … physical activities as
in everyday life, in a group, in a center where other
activities are possible, with various options … just
whatever is useful …” (No. 13, m, 59 years)
“Then, I would also very much like a change of scenery
… one gets up, one goes to the coffee machine early in
the morning – that is compulsory – and then the cup
and … and then: Is something missing? The cigarettes,
yes. Then I would be able to … block out the
environment and all the habits.” (No 5, f, 59 years)
The patients also felt that comprehensive informa-
tion about the risks and consequences of smoking
should be presented in a visual and drastic form, as
part of the consulting services at rehabilitation clinics.
According to them, one option was to show videos of
COPD patients in the final stages of the disease. Other
patients preferred to touch the lung of a deceased
smoker.
“… Then we also spoke about nutrition – that one
basically only gains 2.5 to 3.5 k through metabolism
alone, and the rest comes from frustrated binging or
perhaps from another habit … That was actually a
very good thing.” (No. 17, m, 59 years)
“Well, it would have to be something very effective. For
example, if you go on the Internet and enter “COPD”
you will see several people. I downloaded a film from
YouTube about a woman who smoked for 35 years.
And now her life is hanging on a silken thread … and
this woman is not old. Look! That is the final stage!”
(No. 1, f, 53 years)
During the interviews, it became evident that the
patients considered it important to have a person who
could provide them with emotional support, and who
was available at all times of the day, in person, by tele-
phone, or by e-mail. They felt that this person should
be part of the rehabilitation process. The patients
believed that emotional support was important in re-
ducing their negative attitude, which is one of the side
effects of withdrawal.
“However, one would need to be given the feeling …
that if you – what do I know – make several calls a
day … it’s also okay and not associated with an
unpleasant feeling … according to the motto “Oh! It’s
him again!” (No. 8, f, 56 years)
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In summary, behavioral therapeutic measures are useful
in supporting the smoking cessation process. Nevertheless,
it is important that the major criteria, such as strong
group cohesion, a pleasant atmosphere, a moderator
who has dealt with the disease, and a memorable and
content-related design, be fulfilled. Those requirements
may be accomplished through the implementation of a
rehabilitation program for smoking addiction with the
above named characteristics.
Experiences with alternative approaches for smoking
cessation
In our sample, the patients had tried e-cigarettes, hypno-
sis, acupuncture, and healing touch therapy (see Table 4).
In sum, e-cigarettes is unknown compared to other
methods, such as acupuncture and hypnosis. Two patients
had used e-cigarettes with nicotine, and both stated that
they were uncertain about the risks and long-term side ef-
fects of using e-cigarettes. A drawback of e-cigarettes that
was identified by the patients was the lack of satisfaction
stemming from the fact that one can never ‘finish’ smok-
ing an e-cigarette.
“We have also tried it, but e-cigarette could be more
dangerous than normal cigarettes, because it has not
been researched.” (No. 18, f, 64 years)
The advantages of e-cigarettes that were mentioned
were their reasonable cost and their ability to serve as a
substitute for cigarettes because they provided the pa-
tients with the sensation of smoking actual cigarettes.
The patients also stated that the e-cigarettes were better
for usage around family and friends because they re-
duced exposure to passive smoke and smelled less than
normal cigarettes.
“That way I still have the feeling that I am smoking,
but without having bad breath, bothering others, and
poisoning anyone.” (No. 15, m, 59 years)
Only two of the patients had undergone hypnosis for
smoking cessation; however, more patients had heard
about experiences with hypnosis from family and friends.
Neither of the two patients were satisfied with hypnosis,
as it was unsuccessful in helping them to stop smoking.
One patient managed to abstain from smoking for 4 weeks
after hypnosis but long-term abstinence was not realized.
Nevertheless, hypnosis did help the patients learn strat-
egies, such as distraction and self-motivation techniques
(e.g. autosuggestion) to combat tobacco cravings.
“Yes, we could then also visualise … so, first of all, the
smoking behaviour, why we smoke. But he packaged it
Table 4 Information about alternative methods
Have heard about … Have used…
Number Hypnosis Acupuncture E-cigarette Self-help books and CDs Hypnosis Acupuncture E-cigarette Self-help books and CDs
1 ✓ ✓ X ✓ X ✓ X X
2 X ✓ X ✓ X ✓ X ✓ (book and CD)
3 ✓ ✓ ✓ ✓ X X X ✓ (book)
4 X ✓ X ✓ ✓ ✓ X ✓ (book and diary)
5 ✓ ✓ ✓ ✓ X X X X
6 ✓ ✓ X ✓ X X n.a. X
7 X X X X X X X X
8 ✓ ✓ X ✓ ✓ ✓ n.a. ✓ (CD)
9 X X X X X X X X
10 X X X X X X X X
11 X X X X X X X X
12 ✓ ✓ X ✓ X ✓ n.a. ✓ (book)
13 ✓ ✓ X X X X n.a. X
14 X X ✓ X X X n.a. X
15 X X ✓ X X X ✓ n.k.
16 X ✓ X X X X X X
17 ✓ ✓ X X X X X X
18 ✓ X ✓ X X X ✓ X
✓ have heard about the therapy or have used it
X not known before or not used before
n.a. not available
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more like, yes – like an art show. You see? It was … it
went easily, but somewhere along the line it stopped
anyway. Also lots of positive assimilation. These also
have an influence… ” (No. 8, f, 56 years)
The main reasons the patients did not opt for hypnosis
was its high cost and their unwillingness to spend so
much money on a therapy with a low probability of suc-
cess. Most of the patients were not convinced that hypno-
sis could help a person stop smoking.
“And I said that if I went there five or six times, and
then had to pay, what do I know, 1000 EUR. And it
didn’t work. Then I would say, I don’t know, one
would have to give me a guarantee and say, “So, now
you have really done it!” That would be okay for me.
Then I would do it.” (No. 6, f, 58 years)
The patients were disappointed because they experi-
enced no benefits from the therapy. Three patients had
undergone acupuncture therapy and most of the others
had heard about it from family and friends. The patients
reported that acupuncture helped to reduce smoking
cravings only for a few days, and one patient complained
of experiencing a burning sensation in the ears.
“Well, I just think it did not bring very much – there
was 1 or 2 days.” (No.12, f, 59 years)
Given the fact that COPD patients are highly dependent
on cigarettes, some of them visited healers who used an
energy-based approach to healing, called healing touch.
This type of therapy involves practitioners’ use of their
hands to influence the human energy system. Most of the
patients believed that the healers were interested only if
the person who visited them believed in supernatural
powers. The patients stated that the healer helped them in
terms of increasing their motivation to stop smoking, al-
though only for a limited period. One patient mentioned
that the motivation to stop smoking lasted for only 1 day.
“Oh, well. That’s the way it was. So. Perhaps it was all
nonsense. But this nonsense must have been so credible
that many people perhaps tried just as hard as I did.”
(No. 3, f, 54 years)
Patients reported different experiences with the different
therapies, and achieved different results. Some patients
were unable to stop smoking, whereas others managed to
stop smoking for 4 weeks or longer.
Only one current smoker had experience with an alter-
native approach (e-cigarette) for smoking cessation,
whereas no other current smokers wanted to use alterna-
tive approaches because of the bad experiences of friends
and families. They all believed what other people said and
thought that the methods were too expensive.
All different experiences were sorted using the factors of
the COM-B framework. Figure 1 shows the main results
of the analysis of the three different smoking cessation
methods on each of the factors of capability, opportunity,
and motivation.
Discussion
The COPD patients had varying experiences with differ-
ent smoking cessation therapies. By analysing the inter-
views, we identified the patients’ positive and negative
experiences with the major smoking cessation therapies
currently available in Germany, and their preferences for
the improvement of the smoking cessation process. In
the following section we compared the results according
to the COM-B Model with the existing literature.
Medications
Patients reacted favorably to taking medications for sup-
port during the smoking cessation process, especially to
take a deep breath and thereby attenuate smoking crav-
ings. However, they often criticized the medications’
high costs and side effects. In Germany, medications for
smoking cessation are excluded by law (§34 SGB V)
from reimbursement by compulsory health insurance
[13]; therefore, patients have to pay for these medica-
tions themselves. In Europe, most of the countries reim-
burse at least one form of counselling but only some
countries, (e.g. the UK) reimburse medications for smok-
ing cessation [14]. The costs for both therapies, NRT
and cessation programs are covered in the United King-
dom, Ireland, Denmark and France [15, 16]. A study
from the Netherlands assessed the impact of changes in
reimbursement policy on the use of and adherence to
these medications [17]. The results showed that reim-
bursement of medications was associated with increased
adherence to medication, which should increase the like-
lihood of the medication’s effectiveness. A cost effective-
ness analysis by Cadier et al. show that free access to
cessation treatment in the France health care system is
cost effective and may result in cost savings compared
to a coverage of 50€ [18]. These results indicated that
providing financial support to COPD patients was an op-
tion for improving their motivation during the smoking
cessation process, could change their smoking behavior
and could reduce health care costs in the future.
The reported side effects of the therapies had a nega-
tive influence on the patients’ likelihood of using these
medications, and therefore, a negative influence on the
patients’ motivation. Most side effects were reported
with Vareniclin. Nausea and the more rarely reported
side effects of deafness and loss of body control were
significant disadvantages in this group. The FDA also
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warns against side effects that influence behavior hostil-
ity, agitation and depressed mood [19]. For the different
forms of NRT less side effects were reported. By using
nicotine patches the tingling sensation in the hands and
the daily changes in the skin that came into contact with
the patch were reported negatively. None of the patients
in this study stopped using nicotine patches due to the
side effects. Other results were reported by Eklund et al.
[9]. Some of the patients even stopped using the nicotine
patch due to its powerful side effects. The patients in
our study also complain about the bad taste of chewing
gum. This could be confirmed by other studies that also
provided evidence regarding the unpleasant taste of
nicotine chewing gum [20–22]. Nevertheless the patients
interviewed in this study thought that NRT have few side
effects and could be useful to stop craving. The safety of
the different forms of NRT and small side effects were also
confirmed by other studies and it is therefore the first line
[23, 24].
Our results showed that the use of NRT alone was
not an effective way to quit smoking. It was necessary
to combine the use of NRT with a strong resolution to
quit. The explanation is that NRT motivated the pa-
tients because it helped them take a deep breath.
Nevertheless, a study by van Eerd et al. reported that
cravings did not stop with the aid of NRT [8], and
stopping cravings is a prerequisite to using medications
for motivational support.
Behavioral support
In addition to the medications, patients had experiences
with behavioral support in the form of smoking cessa-
tion seminars. The seminars were the most frequently
discussed method during the interviews. In particular,
the structure and content of the smoking cessation semi-
nars that were identified during the interviews influ-
enced the patients’ motivation to stop smoking. Most of
the smoking cessation seminars in Germany are part of
different rehabilitation programs, which are reimbursed
by self-insurance. One component of this rehabilitation
program is group therapy for smoking cessation. As the
patients in this study frequently complained about the
lack of qualified moderators in the group therapy
sessions, it was not comparable with the holistic ap-
proaches to smoking cessation required in rehabilitation
programs for smokers. One possible reason for the pa-
tients’ lack of acceptance of group therapy might have
been its uncomfortable setting. According to the patients,
the smoking cessation seminars should fulfil certain cri-
teria, for example, education about the health risks of
smoking, providing information about reducing relapse
risk [25], and certification of the trainers. These conditions
Fig. 1 Results according to the three factors of the COM-B Model
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should provide the patients with the possibility and
capability of increasing their motivation (see Fig. 1).
Nevertheless, the guidelines for smoking cessation semi-
nars in Germany have no specific information on the
manner in which the content should be presented. Add-
itionally, the recommendations of the UK’s National
Institute for Health and Care Excellence for group behav-
ior therapies are rather general [26]. They consist of
scheduled meetings where people who smoke receive
information, advice, and encouragement, and some
form of behavioral intervention. Therefore, the trainers
are free to choose their own teaching style (e.g. traditional
teacher-centered instruction and training in group set-
tings). Additionally, there is inadequate information about
strategies for relapse prevention.
One way to improve the quality of these seminars is to
revise the guidelines and add requirements that the semi-
nars should fulfil. These requirements should include the
preferences expressed by the patients, such as visual pre-
sentations of the consequences of smoking in the form of
videos. Another qualitative study by Bethea et al. revealed
that the use of visual media was an important method for
relaying information [27]. Therefore, monitoring the qual-
ity of these seminars should improve their quality and
acceptance by smokers, as an effective way to help them
stop smoking. Improvements in these seminars should
result in smokers’ increased motivation during smoking
cessation. Also other authors mentioned that patients with
COPD need a higher level of support for smoking cessa-
tion [23, 28]. This is clearly apparent in the example of
hospitalization compared with usual care. After 1 year the
authors calculated a quit rate of 52 % for hospitalization
compared to 7 % for usual care. These results underpin
the discussion about the implementation of rehabilitation
programs for smoking cessation.
Alternative methods
The alternative methods for quitting smoking were gener-
ally described as ineffective. This finding is consistent with
a Cochrane review of hypnosis therapy [29]. Nevertheless,
our study’s results showed that hypnosis helped patients
learn new strategies for self-motivation techniques, and
therefore, improved their capabilities. Because only a small
number of interviewed patients had experience with alter-
native methods, no further results were reported.
Strengths and limitations
Overall, this study has several strengths and limitations.
It includes only COPD patients from Germany; thus, the
obtained information on smoking cessation programs is
only from Germany. Nevertheless, the patients’ experi-
ences with medications might be transferred to other
European countries. In addition, the guidelines for the
content of smoking cessation seminars seemed to be
comparable between some countries (e.g. UK and
Germany). The interviews were conducted via tele-
phone, and, in some cases, personally. The patients
interviewed via telephone may have failed to provide
complete answers or may not have answered questions
in the same manner as they would have in the case of a
personal interview. However, these patients provided a
detailed report on the smoking cessation process. We
also integrated more ex-smokers than current smokers
so that the experiences of ex-smokers may be overrep-
resented. Nevertheless this study provides some insight
into the differences between patients with COPD who
are current and former smokers, but in this case, fur-
ther research is necessary. This study also adds to the
existing knowledge about the experiences of patients
with COPD and provides further insight into the prob-
lems of smoking cessation seminars and the improve-
ments needed for their acceptance by the patients. This
study provides COPD patients’ impressions of their ex-
periences with alternative smoking cessation therapies,
such as hypnosis and acupuncture. In summary, our
results provide valuable information about patients’
preferences for smoking cessation methods and can
help improve the smoking cessation process.
Conclusion
We identified several different experiences of patients
with COPD with different smoking cessation therapies.
The findings of this study provide us with a deeper
understanding of which experiences made it easy and
which made it difficult for patients to change their
smoking behaviors. Based on these problems, some im-
provements in smoking cessation programs are neces-
sary to ensure that patients have better experiences and
increased motivation.
We identified experiences with medications, smoking
cessation seminars, and alternative methods of smoking
cessation. High prices and powerful side effects made it
difficult for patients to use medications for smoking
cessation. Nevertheless, the medications helped the pa-
tients to take a deep breath. Based on these experiences,
providing financial support for buying these medications
could reduce the barriers to smoking cessation. The expe-
riences with smoking cessation seminars showed that the
content, structure, and seriousness of these seminars
negatively influenced the patients’ motivation to stop
smoking. Therefore, improvements in the rules for design,
implementation, and supervision of smoking cessation
seminars, and the integration of rehabilitation clinics,
especially for smoking cessation, should be discussed. The
results showed that some negative experiences with smok-
ing cessation were explained by the patients’ lack of
motivation or determination. Other experiences, such as
the structure of smoking cessation seminars or the high
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price for pharmaceuticals should be addressed through
policy changes, which should result in patients’ higher
motivation to quit smoking.
This study adds further information about the experi-
ences that influence the quitting process of patients with
COPD and their preferences for improvement. Further
studies of the differences between patients with COPD
who are current and former smokers are needed. The
findings could provide further insight into the factors
that determine successful cessation.
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